Finasteride's Effect on Prostate Gland in Men with High PSA Levels
Author Information
Author(s): RJ Cote, EC Skinner, CE Salem, SJ Mertes, FZ Stanczyk, BE Henderson, MC Pike, RK Ross
Primary Institution: University of Southern California/Norris Comprehensive Cancer Center
Hypothesis
Reducing the conversion of testosterone to dihydrotestosterone in the prostate with finasteride will reduce the incidence of prostate cancer.
Conclusion
The study found little evidence that finasteride is an effective chemopreventive agent for prostate cancer in men with elevated PSA levels.
Supporting Evidence
- Finasteride treatment resulted in a 48% reduction in PSA levels.
- DHT levels decreased by 67% in the finasteride group.
- 30% of patients treated with finasteride had prostate cancer detected after 12 months.
Takeaway
This study looked at whether a drug called finasteride could help prevent prostate cancer in men with high PSA levels, but it didn't really work.
Methodology
Men aged 50 and older with elevated PSA levels were randomized to receive finasteride or no medication for 12 months, followed by biopsies.
Potential Biases
Potential bias in cancer detection due to reduced prostate size from finasteride treatment.
Limitations
The study only included men with elevated PSA and no prior prostate cancer, which may limit generalizability.
Participant Demographics
Men aged 50 and older, average age 68, with elevated serum PSA levels.
Statistical Information
P-Value
P < 0.001 for PSA and DHT reductions; P = 0.025 for cancer detection in treatment group.
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website